Anacor Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
18
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Boron-containing small molecules as antiprotozoal agents (US 10,301,329) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 4, 2026The maintenance fee for Tricyclic Benzoxaborole Compounds and Uses Thereof (US 10,308,668) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for Novel Oxaborole Analogs and Uses Thereof (US 11,691,992) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Mar 29, 2027The maintenance fee for Boron-containing small molecules (US 9,145,429) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Crystal forms of crisaborole in free form and preparation method and use thereof (US 11,773,113) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 2 fees due Jul 7 to 14, 2027 · next Jul 7
- 1 fee due Aug 18, 2027The maintenance fee for Oxaborole Esters and Uses Thereof (US 10,562,921) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,767,657 | Boron-containing small molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 8,501,712 | Boron-Containing Small Molecules as Anti-Inflammatory Agents In force · Medium confidence | In force | Medium confidence | |
| US 9,029,353 | Boron-Containing Small Molecules as Anti-Inflammatory Agents In force · Medium confidence | In force | Medium confidence | |
| US 9,682,092 | Boron-Containing Small Molecules as Anti-Inflammatory Agents In force · Medium confidence | In force | Medium confidence | |
| US 8,106,031 | Hydrolytically-resistant boron-containing therapeutics and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,796,735 | Boron-containing small molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 10,533,021 | Boron-containing small molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 7,816,344 | Boron-containing small molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 8,461,135 | Boron-containing small molecules as anti-inflammatory agents In force · From the USPTO record | In force | From the USPTO record | |
| US 9,012,431 | Boron-Containing Small Molecules as Anti-Inflammatory Agents In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 47: 22 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 14 abandoned · 29 no status recorded